André Tadic

Title: André Tadic: Innovator in Antidepressant Response Prediction

Introduction

André Tadic is a notable inventor based in Flörsheim am Main, Germany. He has made significant contributions to the field of pharmacogenetics, particularly in predicting patient responses to monoaminergic antidepressants. His innovative approach has the potential to enhance treatment efficacy for individuals suffering from depression.

Latest Patents

André Tadic holds a patent titled "Susceptibility to and stratification for monoaminergic antidepressants." This invention outlines a method for predicting a patient's response to monoaminergic antidepressants by determining the DNA-methylation status of a brain-derived neurotrophic factor (BDNF) gene promoter. The method involves three key steps: assessing the DNA-methylation status, attributing hypomethylation to non-response, and linking normal or hypermethylation to a positive response. This patent represents a significant advancement in personalized medicine.

Career Highlights

Throughout his career, André Tadic has worked with prestigious institutions, including the Medical University of Hannover and the University Medical Center of Johannes Gutenberg University Mainz. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

André Tadic has collaborated with notable colleagues such as Helge Frieling and Stefan Bleich. These partnerships have fostered a collaborative environment that promotes innovation and the advancement of medical research.

Conclusion

André Tadic's contributions to the field of antidepressant response prediction highlight the importance of personalized medicine. His innovative patent and collaborations with esteemed institutions and colleagues underscore his commitment to improving patient outcomes in mental health treatment.